Steven Valiquette
Stock Analyst at Mizuho
(2.89)
# 1,584
Out of 4,784 analysts
107
Total ratings
59.26%
Success rate
3.4%
Average return
Main Sectors:
Stocks Rated by Steven Valiquette
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALGN Align Technology | Maintains: Outperform | $295 → $250 | $159.21 | +57.03% | 10 | Mar 25, 2025 | |
| XRAY DENTSPLY SIRONA | Maintains: Neutral | $21 → $18 | $14.93 | +20.56% | 7 | Mar 13, 2025 | |
| SOLV Solventum | Maintains: Neutral | $70 → $82 | $74.75 | +9.70% | 2 | Mar 3, 2025 | |
| DOCS Doximity | Maintains: Neutral | $55 → $65 | $58.51 | +11.09% | 2 | Feb 10, 2025 | |
| VEEV Veeva Systems | Maintains: Outperform | $275 → $280 | $234.21 | +19.55% | 2 | Dec 9, 2024 | |
| LFMD LifeMD | Initiates: Neutral | $7 | $5.45 | +28.44% | 1 | Dec 4, 2024 | |
| HQY HealthEquity | Initiates: Outperform | $126 | $86.96 | +44.89% | 1 | Dec 4, 2024 | |
| HSIC Henry Schein | Initiates: Neutral | $75 | $68.62 | +9.30% | 5 | Dec 4, 2024 | |
| TALK Talkspace | Initiates: Outperform | $5 | $2.63 | +90.11% | 1 | Dec 4, 2024 | |
| NVST Envista Holdings | Initiates: Underperform | $20 | $16.97 | +17.86% | 1 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $14 | $8.58 | +63.17% | 7 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $142 | $186.18 | -23.73% | 10 | Sep 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 | $68.76 | -20.01% | 6 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $82 → $92 | $153.42 | -40.03% | 10 | Aug 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $85 | $136.44 | -37.70% | 5 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $565 | $516.04 | +9.49% | 5 | Apr 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $100 | $67.14 | +48.94% | 1 | Mar 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $6.04 | +131.79% | 1 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $380 → $400 | $322.85 | +23.90% | 4 | Oct 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Overweight | $107 | $60.04 | +78.21% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $22 → $17 | $28.96 | -41.30% | 3 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $5 → $12 | $6.15 | +95.12% | 1 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $96 | $100.78 | -4.74% | 3 | Nov 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $166 | $668.06 | -75.15% | 2 | Nov 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $105 → $120 | $167.33 | -28.29% | 6 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $117 → $127 | $342.16 | -62.88% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $327 → $358 | $264.58 | +35.31% | 3 | Dec 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $20 → $16 | $31.21 | -48.73% | 3 | Aug 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $78 → $60 | $11.19 | +436.19% | 3 | Apr 3, 2019 |
Align Technology
Mar 25, 2025
Maintains: Outperform
Price Target: $295 → $250
Current: $159.21
Upside: +57.03%
DENTSPLY SIRONA
Mar 13, 2025
Maintains: Neutral
Price Target: $21 → $18
Current: $14.93
Upside: +20.56%
Solventum
Mar 3, 2025
Maintains: Neutral
Price Target: $70 → $82
Current: $74.75
Upside: +9.70%
Doximity
Feb 10, 2025
Maintains: Neutral
Price Target: $55 → $65
Current: $58.51
Upside: +11.09%
Veeva Systems
Dec 9, 2024
Maintains: Outperform
Price Target: $275 → $280
Current: $234.21
Upside: +19.55%
LifeMD
Dec 4, 2024
Initiates: Neutral
Price Target: $7
Current: $5.45
Upside: +28.44%
HealthEquity
Dec 4, 2024
Initiates: Outperform
Price Target: $126
Current: $86.96
Upside: +44.89%
Henry Schein
Dec 4, 2024
Initiates: Neutral
Price Target: $75
Current: $68.62
Upside: +9.30%
Talkspace
Dec 4, 2024
Initiates: Outperform
Price Target: $5
Current: $2.63
Upside: +90.11%
Envista Holdings
Dec 4, 2024
Initiates: Underperform
Price Target: $20
Current: $16.97
Upside: +17.86%
Nov 5, 2024
Maintains: Equal-Weight
Price Target: $18 → $14
Current: $8.58
Upside: +63.17%
Sep 21, 2023
Maintains: Equal-Weight
Price Target: $142
Current: $186.18
Upside: -23.73%
Aug 4, 2023
Maintains: Overweight
Price Target: $55
Current: $68.76
Upside: -20.01%
Aug 2, 2023
Maintains: Overweight
Price Target: $82 → $92
Current: $153.42
Upside: -40.03%
Jun 12, 2023
Maintains: Equal-Weight
Price Target: $80 → $85
Current: $136.44
Upside: -37.70%
Apr 14, 2023
Maintains: Overweight
Price Target: $565
Current: $516.04
Upside: +9.49%
Mar 30, 2023
Maintains: Overweight
Price Target: $110 → $100
Current: $67.14
Upside: +48.94%
Feb 27, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $6.04
Upside: +131.79%
Oct 28, 2022
Maintains: Overweight
Price Target: $380 → $400
Current: $322.85
Upside: +23.90%
Jul 28, 2022
Reinstates: Overweight
Price Target: $107
Current: $60.04
Upside: +78.21%
Apr 18, 2022
Downgrades: Equal-Weight
Price Target: $22 → $17
Current: $28.96
Upside: -41.30%
Jun 11, 2021
Upgrades: Overweight
Price Target: $5 → $12
Current: $6.15
Upside: +95.12%
Nov 23, 2020
Upgrades: Overweight
Price Target: $96
Current: $100.78
Upside: -4.74%
Nov 2, 2020
Upgrades: Overweight
Price Target: $166
Current: $668.06
Upside: -75.15%
Apr 30, 2020
Reiterates: Neutral
Price Target: $105 → $120
Current: $167.33
Upside: -28.29%
Apr 22, 2020
Maintains: Overweight
Price Target: $117 → $127
Current: $342.16
Upside: -62.88%
Dec 6, 2019
Maintains: Overweight
Price Target: $327 → $358
Current: $264.58
Upside: +35.31%
Aug 30, 2019
Maintains: Underweight
Price Target: $20 → $16
Current: $31.21
Upside: -48.73%
Apr 3, 2019
Maintains: Equal-Weight
Price Target: $78 → $60
Current: $11.19
Upside: +436.19%